Back to the main directory
Company Analysis / Equity
- Morningstar | Tsingtao’s 1Q19 Result Beat From Strong Premium Beer Growth, but Shares Remain Overvalued by Morningstar
- Morningstar | Allianz's 1Q: Good Life and Non-Life; Poorer Showing Asset Management; Stock Fairly Valued by Morningstar
- Morningstar | K+S Expects Higher Profits in 2019; Maintaining Our EUR 17.50 FVE With Outlook Intact by Morningstar
- Morningstar | Tsingtao’s 1Q19 Result Beat From Strong Premium Beer Growth, but Shares Remain Overvalued by Morningstar
- Morningstar | Guangshen’s 2018 Result Implies a Net Loss in 4Q; Cutting FVE to HKD 5.80, Shares Remain Undervalued by Morningstar
- No Mud Will Stick on Anta, Fair Value Maintained At HKD 55 by Morningstar
- Morningstar | BOC Hong Kong Posts Solid Fiscal 2018 Result; Bank Remains Undervalued by Morningstar
- Morningstar | Platinum’s Better FUM Growth So Far in 2019 Not Enough to Offset Prior Underperformance, FVE Cut by Morningstar
- Morningstar | STERV Updated Forecasts and Estimates from 10 Apr 2019 by Morningstar
- Morningstar | KNEBV Updated Forecasts and Estimates from 10 Apr 2019 by Morningstar
- Komatsu’s Fiscal 2019 in Line; Fiscal 2020 Guidance Weaker than Expected; FVE Cut to JPY 2,680 by Morningstar
- Morningstar | We Increase Our Fair Value Estimate for Narrow-Moat Compass to GBX 1,750; Shares Fairly Valued by Morningstar
- Morningstar | ASML Overcomes Industry Weakness with Solid 2Q Results; Shares Remain Overvalued by Morningstar
- Morningstar | Like Peers, Wipro Has a Slower-Than-Expected Start to the Year; Shares Fairly Valued by Morningstar
- Morningstar | 00410 Updated Forecasts and Estimates from 24 May 2019 by Morningstar
- Nissin Looks Overseas for Growth by Morningstar
- Chr. Hansen Reports 2Q Results, Announces Pharma Joint Venture With Lonza; Shares Rich by Morningstar
- Zoomlion’s Fiscal-Year 2018 in Line; FVE Raised, Shares Remain Overvalued on Long-Term Uncertainties by Morningstar
- Reducing Our Mosaic FVE to $35 on Lower Near-Term Phosphate Prices; Shares Undervalued by Morningstar
- Morningstar | Transitioning SCA Property to a New Analyst. See Updated Analyst Note from 24 May 2019 by Morningstar
- AbbVie’s Acquisition of Allergan Looks Opportunistic and Offers Diversification From Humira by Morningstar
- Morningstar | Arena Sensibly Raises Capital to Expand its Portfolio by Morningstar
- Empire State Realty Trust Reports Tepid 1Q Earnings; Maintaining FVE by Morningstar
- Morningstar | Vale’s Misfortune Priced into the Iron Ore Miners but Value Emerging in Base Metals and Coal. See Updated Analyst Note from 12 Jul 2019 by Morningstar
- Orsted Is Fit to Beat Its Medium-Term Wind-Capacity Growth Targets by Morningstar